Welcome to our dedicated page for Atyr Pharma news (Ticker: ATYR), a resource for investors and traders seeking the latest updates and insights on Atyr Pharma stock.
aTyr Pharma, Inc. (Nasdaq: ATYR) is a clinical stage biotechnology company whose news flow centers on the development of first-in-class medicines from its proprietary tRNA synthetase platform. The company’s updates frequently highlight progress with its lead biologic immunomodulator, efzofitimod, in interstitial lung disease indications such as pulmonary sarcoidosis and systemic sclerosis-related interstitial lung disease.
Investors following ATYR news can expect regular announcements on clinical trial milestones, including topline data, interim analyses and additional findings from key studies. Recent disclosures have covered the global Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis, where the primary endpoint related to steroid reduction was not met but clinical improvements were reported across several pre-specified measures, and the Phase 2 EFZO-CONNECT™ study in systemic sclerosis-related ILD, where interim data described stable or improved skin scores and biomarker trends with efzofitimod.
aTyr’s news stream also includes scientific and medical conference presentations, such as late-breaking oral abstracts at the European Respiratory Society Congress and talks at specialized meetings on aminoacyl-tRNA synthetase research. These items provide additional context on the company’s tRNA synthetase biology platform and its approach to treating fibrotic lung diseases.
In addition, ATYR issues corporate and financial updates, including quarterly results, cash position discussions, equity-related announcements such as inducement stock option grants, and notices about inclusion in market indices like the Russell 2000 and Russell 3000. For readers tracking developments in clinical-stage respiratory and fibrosis-focused biotechnology, the ATYR news page offers a consolidated view of the company’s clinical progress, platform evolution and key corporate events.
aTyr Pharma (Nasdaq: ATYR) has appointed Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise. Rayes brings over 25 years of experience in commercial organizations and rare disease product launches. This strategic hire comes ahead of the company's Phase 3 EFZO-FIT™ study readout for efzofitimod in pulmonary sarcoidosis, expected in Q3 2025.
Rayes previously served as Senior Vice President, Head of Commercial at ChemoCentryx, where she led the TAVNEOS® launch before Amgen's acquisition. At Actelion Pharmaceuticals, she held key commercial roles and led the VALCHLOR® rare disease franchise and OPSUMIT® launch.
As part of her appointment, Rayes received a stock option grant for 225,000 shares at $3.49 per share, vesting over four years. The company aims to potentially deliver the first new treatment for pulmonary sarcoidosis in more than 70 years.
aTyr Pharma has announced its Q4 and full year 2024 results, highlighting key developments in its clinical programs. The company completed enrollment for its global pivotal Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis, with topline data expected in Q3 2025. The study, involving 268 patients across 85 centers in nine countries, received its fourth positive DSMB review.
The company's cash position stood at $75.1 million as of December 31, 2024, with an additional $18.8 million raised through ATM offering. R&D expenses were $54.4 million, while G&A expenses totaled $13.8 million for 2024. The company's cash runway is expected to extend one year beyond the Phase 3 readout, including potential BLA filing.
Additionally, enrollment continues in the Phase 2 EFZO-CONNECT™ study for systemic sclerosis-related interstitial lung disease, with interim data expected in Q2 2025. A key manuscript demonstrating efzofitimod's immunomodulatory activity was published in Science Translational Medicine.
aTyr Pharma has announced a significant publication in Science Translational Medicine validating the mechanism of action of efzofitimod, their lead therapeutic candidate. The research demonstrates efzofitimod's unique anti-inflammatory mechanism targeting macrophages through the neuropilin-2 (NRP2) receptor.
The publication details how efzofitimod, derived from histidyl-tRNA synthetase (HARS), binds specifically to NRP2, which is highly expressed in inflammatory sites. This binding inhibits pro-inflammatory receptors and cytokines, potentially disrupting chronic inflammation and fibrosis cycles.
Currently, efzofitimod is undergoing a global Phase 3 EFZO-FIT™ study for pulmonary sarcoidosis and a Phase 2 EFZO-CONNECT™ study for systemic sclerosis-related ILD. The drug has received orphan drug designation in the U.S., E.U., and Japan for sarcoidosis, and Fast Track designation in the U.S. for both pulmonary sarcoidosis and SSc-ILD.
aTyr Pharma announced a fourth positive safety review by an independent data and safety monitoring board (DSMB) for its Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis patients. The DSMB recommended continuing the study without modifications, reinforcing the therapeutic candidate's favorable safety profile.
The global Phase 3 study involves 268 subjects across multiple centers in the United States, Europe, Japan, and Brazil. The 52-week trial includes three parallel cohorts randomized to receive either 3.0 mg/kg or 5.0 mg/kg of efzofitimod or placebo, administered intravenously monthly for 12 doses. The study's primary endpoint focuses on steroid reduction, with secondary endpoints measuring lung function and sarcoidosis symptoms.
Efzofitimod is a first-in-class biologic immunomodulator targeting interstitial lung disease (ILD). The company expects to report topline results in Q3 2025.
aTyr Pharma (Nasdaq: ATYR), a clinical stage biotechnology company focused on developing first-in-class medicines from its tRNA synthetase platform, has scheduled its Fourth Quarter and Full Year 2024 financial results announcement and corporate update for March 13, 2025, after market close.
The company will host a conference call and webcast at 5:00 PM EDT / 2:00 PM PDT on the same day. Participants can join via telephone by registering through the provided dial-in link to receive their personalized PIN code, or attend the live webcast through the company's investor events page.
aTyr Pharma (Nasdaq: ATYR), a clinical stage biotechnology company, has announced its participation in the Leerink Partners Global Healthcare Conference in Miami, FL, scheduled for March 9-12, 2025. Dr. Sanjay S. Shukla, President and CEO, will present in a fireside chat format on Monday, March 10, 2025, at 1:40pm EDT.
The company, which focuses on developing first-in-class medicines from its proprietary tRNA synthetase platform, will make the presentation available via webcast on their investor website, with a replay accessible for 90 days afterward. Management will also conduct one-on-one meetings with registered conference attendees.
aTyr specializes in translating tRNA synthetase biology into therapies for fibrosis and inflammation. Their lead candidate, efzofitimod, is a first-in-class biologic immunomodulator being developed for interstitial lung disease treatment. The company's platform focuses on uncovering signaling pathways through domains derived from all 20 tRNA synthetases.
aTyr Pharma (ATYR) has announced its upcoming presentation of three posters featuring efzofitimod at the American Thoracic Society (ATS) 2025 International Conference in San Francisco from May 16-21, 2025. The presentations will cover:
1. The EFZO-FIT trial design and patient characteristics, showcasing the largest placebo-controlled trial in pulmonary sarcoidosis
2. Real-world treatment patterns among pulmonary sarcoidosis patients in the US
3. Incidence, prevalence, and mortality data for pulmonary sarcoidosis with parenchymal involvement in the US
Efzofitimod, their lead therapeutic candidate, is a first-in-class biologic immunomodulator being developed for interstitial lung disease (ILD). It's currently under investigation in two clinical trials: the global Phase 3 EFZO-FIT™ study for pulmonary sarcoidosis and the Phase 2 EFZO-CONNECT™ study for systemic sclerosis-related ILD. Topline data from the Phase 3 study is expected in Q3 2025.
aTyr Pharma (ATYR), a clinical stage biotechnology company, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's CEO, Sanjay S. Shukla, will deliver a corporate presentation on Thursday, January 16, 2025, at 8:15am PST in San Francisco.
The company specializes in developing first-in-class medicines from its proprietary tRNA synthetase platform. Their lead therapeutic candidate, efzofitimod, is a first-in-class biologic immunomodulator being developed for interstitial lung disease treatment. The presentation will be webcasted and available on the company's website for at least 30 days afterward.
aTyr's platform focuses on unlocking therapeutic intervention points through signaling pathways driven by domains derived from all 20 tRNA synthetases, which are ancient proteins that have evolved to regulate diverse extracellular pathways in humans.
aTyr Pharma (Nasdaq: ATYR) has appointed Eric Benevich to its Board of Directors, effective December 10, 2024. Benevich, who currently serves as Chief Commercial Officer at Neurocrine Biosciences, brings over 30 years of pharmaceutical industry experience. He has previously held positions at AstraZeneca, Amgen, Peninsula Pharmaceuticals, and Avanir Pharmaceuticals, where he was involved in the sales and marketing of notable drugs including Prilosec®, Epogen®, Enbrel®, and Neudexta®.
aTyr is a clinical-stage biotechnology company focused on developing first-in-class medicines from its tRNA synthetase platform. Their lead candidate, efzofitimod, is being developed for the treatment of interstitial lung disease.
aTyr Pharma announced positive results from the third pre-planned interim safety analysis of its Phase 3 EFZO-FIT™ study for efzofitimod in pulmonary sarcoidosis patients. The independent Data and Safety Monitoring Board (DSMB) reviewed data from all 268 enrolled patients and recommended continuing the study without modifications.
The EFZO-FIT™ study is a global Phase 3 randomized, double-blind, placebo-controlled trial evaluating efzofitimod's efficacy and safety. The 52-week study includes three parallel cohorts randomized to receive either 3.0 mg/kg, 5.0 mg/kg of efzofitimod, or placebo monthly for 12 doses. The trial's primary endpoint is steroid reduction, with secondary endpoints measuring lung function and sarcoidosis symptoms.